Investor Conference CallQ2 2012 ResultsJuly 31, 2012 / Marijn Dekkers, CEO
DisclaimerThis presentation may contain forward-looking statements based on currentassumptions and forecasts made by Bayer...
2nd Quarter 2012 –Strong Operating Performance Delivered record sales, lower reported EBIT due to high special     charge...
2nd Quarter 2012 –Strong Operating PerformanceSales                                  EBIT                   EBITDA        ...
Regional Performance–Growth Led By USA and Emerging EconomiesIn € million, ∆% yoy Fx adjusted        Q2’12 Group Sales by ...
2nd Quarter 2012 –Cash Flow And Net Debt DevelopmentCash Flow in € million, Net Debt in € billion                         ...
HealthCare –Record Operating Performance, Outlook RaisedIn € million, ∆% yoy, () = Fx & portf. adjusted                   ...
CropScience –Strong Momentum Continues, Outlook RaisedIn € million, ∆% yoy, () = Fx & portf. adjusted                     ...
MaterialScience –Further ImprovedIn € million, ∆% yoy, () = Fx & portf. adjusted                            Q2’12 Sales   ...
Fiscal 2012 –Group Outlook Raised SignificantlySales ∆ Fx & portf. adjusted, EBITDA before special items                  ...
Fiscal 2012 –Guidance By Subgroup                                            Raised: HealthCare                           ...
Investor Conference CallQ2 2012 ResultsJuly 31, 2012 / Marijn Dekkers, CEO
Upcoming SlideShare
Loading in …5
×

Q2 2012 Investor Conference Call Presentation

511 views

Published on

Q2 2012 Investor Conference Call Presentation

Published in: Investor Relations
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
511
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Q2 2012 Investor Conference Call Presentation

  1. 1. Investor Conference CallQ2 2012 ResultsJuly 31, 2012 / Marijn Dekkers, CEO
  2. 2. DisclaimerThis presentation may contain forward-looking statements based on currentassumptions and forecasts made by Bayer Group or subgroup management.Various known and unknown risks, uncertainties and other factors could lead tomaterial differences between the actual future results, financial situation,development or performance of the company and the estimates given here.These factors include those discussed in Bayer’s public reports which areavailable on the Bayer website at www.bayer.com.The company assumes no liability whatsoever to update these forward-lookingstatements or to conform them to future events or developments.Page 2 • Investor Handout • Q2 2012
  3. 3. 2nd Quarter 2012 –Strong Operating Performance Delivered record sales, lower reported EBIT due to high special charges but nicely improved adj. earnings Significant positive currency effects Strong operating momentum broadly based:  HealthCare with best quarter ever  CropScience at new record for 2nd quarter performance  MaterialScience with record quarterly sales and highest adj. EBITDA for a second quarter since 2007 Full year 2012 financial outlook raised significantly: 4-5% organic growth and core EPS up ~10%Page 3 • Investor Handout • Q2 2012
  4. 4. 2nd Quarter 2012 –Strong Operating PerformanceSales EBIT EBITDA Core EPSin € million adjusted*% currency & portfolio adj. in € million in € million in € 10,177 2,172 9,252 2,035 1.47 1.29 1,273 750 Q2’11 Q2’12 Q2’11 Q2’12 Q2’11 Q2’12 Q2’11 Q2’12 +5% -41% +7% +14% *before special items Page 4 • Investor Handout • Q2 2012
  5. 5. Regional Performance–Growth Led By USA and Emerging EconomiesIn € million, ∆% yoy Fx adjusted Q2’12 Group Sales by Region Emerging Economies Emerging +6% USA Economies¹ ~1,510 +10% +7% 22% 36% +14% ~1,020 +10% 31% ~700 Western 11% -4% Others² Europe +7% ~460 -2% Group €10,177m; +5% Emerging Latin Eastern Africa & Asia³ America Europe Middle East ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern EuropePage 5 • Investor Handout • Q2 2012 ² Others = Japan, Australia, New Zealand, Canada ³ Emerging Asia = Asia w/o Japan, Australia, New Zealand
  6. 6. 2nd Quarter 2012 –Cash Flow And Net Debt DevelopmentCash Flow in € million, Net Debt in € billion Q2’12 Cash Flow Net Debt Development GCF NCF Invest- oFCF +€1,060m cont. ments 7.9 6.9 1,226 1,369 444 925 ∆% y-o-y -20 -11 +49 -25 Q1´12 Q2´12Page 6 • Investor Handout • Q2 2012
  7. 7. HealthCare –Record Operating Performance, Outlook RaisedIn € million, ∆% yoy, () = Fx & portf. adjusted Q2’12 Sales Earnings Consumer Adj. Adj. 36% Pharma Health EBITDA* EBIT* +10% (+4%) +9% (+4%) 1,943 2,685 1,248 +8% 1,156 902 +8% 809 +12% 837 722 502 571 +14% HealthCare €4,628m; +10% (+4%) 434 439 +1% 335 331 -1% Price Volume Fx Portfolio +1% +3% +6% 0% Q2‘11 Q2‘12 Q2‘11 Q2‘12 *before special itemsPage 7 • Investor Handout • Q2 2012
  8. 8. CropScience –Strong Momentum Continues, Outlook RaisedIn € million, ∆% yoy, () = Fx & portf. adjusted Q2’12 Sales Earnings Environmental Crop Protection Adj. Adj. Science +18% (+14%) EBITDA* EBIT* +2% (-4%) 189 1,850 549 +17% 237 471 435 +23% 353 BioScience+22% (+21%) CropScience €2,276m; +17% (+13%) Price Volume Fx Portfolio +2% +11% +5% -1% Q2‘11 Q2‘12 Q2‘11 Q2‘12 *before special itemsPage 8 • Investor Handout • Q2 2012
  9. 9. MaterialScience –Further ImprovedIn € million, ∆% yoy, () = Fx & portf. adjusted Q2’12 Sales Earnings Polycarbonates Polyurethanes Adj. Adj. -4% (-10%) +13% (+7%) EBITDA* EBIT* 728 1,547 385 +3% 372 CAS** 507 236 232 -2%+3% (+3%) IO*** 180+15% (+10%) MaterialScience €2,962m; +6% (+2%) Price Volume Fx Portfolio +1% +1% +5% -1% Q2‘11 Q2‘12 Q2‘11 Q2‘12 *before special itemsPage 9 • Investor Handout • Q2 2012 **CAS: Coatings, Adhesives, Specialties *** IO: Industrial Operations
  10. 10. Fiscal 2012 –Group Outlook Raised SignificantlySales ∆ Fx & portf. adjusted, EBITDA before special items ∆ vs. 2012E 2012E 2011 2010 Original Actual ~3% or 4-5% to Sales €36.5bn +6% ~€37bn €39-40bn* High single-digit Adj. EBITDA €7.6bn +7% Slightly improve % increase Core EPS €4.83 +15% Slightly improve ~10% *Assuming Fx rates end of Q2’2012Page 10 • Investor Handout • Q2 2012 Outlook depends on specific planning assumptions as detailed in the Annual/Quarterly Report
  11. 11. Fiscal 2012 –Guidance By Subgroup Raised: HealthCare Sales to increase 3% to 4%. Adj. EBITDA to grow by mid- to high-single-digit percentage. Raised: Pharma Sales to increase slightly. Adj. EBITDA to grow mid-single-digit percentage. Raised: Consumer Sales to increase mid-single-digit percentage. Health Adj. EBITDA to grow high-single-digit percentage. Raised: CropScience Sales to increase by ~10%. Adj. EBITDA to grow by ~20%. Unchanged: Sales and adj. EBITDA to remain level with prior year. MaterialScience Q3’12: Aspire to achieve sales and adj. EBITDA on good Q2’12 level. Sales ∆ Fx & portf. adjusted, EBITDA before special itemsPage 11 • Investor Handout • Q2 2012 Outlook depends on specific planning assumptions as detailed in the Annual/Quarterly Report
  12. 12. Investor Conference CallQ2 2012 ResultsJuly 31, 2012 / Marijn Dekkers, CEO

×